Benitec Biopharma Inc. (BNTC)
| Previous close | 0.3187 |
| Open | 0.3200 |
| Bid | 0.3423 x 4000 |
| Ask | 0.3640 x 1000 |
| Day's range | 0.3187 - 0.3449 |
| 52-week range | 0.3010 - 3.9000 |
| Volume | |
| Avg. volume | 331,630 |
| Market cap | 8.863M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1720 |
| Earnings date | 14 Nov 2022 - 18 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- GlobeNewswire
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying
- GlobeNewswire
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purc
- GlobeNewswire
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange C
